Difference between revisions of "18324928. CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING simplified abstract (THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE)"
Wikipatents (talk | contribs) (Creating a new page) |
(No difference)
|
Latest revision as of 10:45, 25 March 2024
Contents
- 1 CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING
- 1.1 Organization Name
- 1.2 Inventor(s)
- 1.3 CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING - A simplified explanation of the abstract
- 1.4 Simplified Explanation
- 1.5 Potential Applications
- 1.6 Problems Solved
- 1.7 Benefits
- 1.8 Potential Commercial Applications
- 1.9 Possible Prior Art
- 1.10 Unanswered Questions
- 1.11 Original Abstract Submitted
CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING
Organization Name
THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE
Inventor(s)
Andrew Garst of Boulder CO (US)
CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING - A simplified explanation of the abstract
This abstract first appeared for US patent application 18324928 titled 'CRISPR ENABLED MULTIPLEXED GENOME ENGINEERING
Simplified Explanation
The abstract describes a method for generating a vector for editing a cell by ligating a portion of a gRNA into a vector that encodes an editing cassette, a promoter, and a gene encoding another portion of the gRNA.
- The method involves ligating a portion of a gRNA into a vector.
- The vector contains an editing cassette, a promoter, and a gene encoding another portion of the gRNA.
- Upon ligation, the portions of the gRNA from the editing cassette and the gene are ligated to form a functional gRNA.
Potential Applications
The technology can be applied in gene editing, genetic engineering, and biotechnology research.
Problems Solved
This technology enables precise editing of cells at the genetic level, allowing for targeted modifications and advancements in genetic research.
Benefits
The method provides a more efficient and accurate way to edit cells, leading to potential breakthroughs in medical treatments and biotechnological applications.
Potential Commercial Applications
The technology can be utilized in pharmaceutical research, biotech companies, and genetic engineering firms to develop new therapies, products, and technologies.
Possible Prior Art
Prior art may include similar methods for generating vectors for gene editing, such as CRISPR-Cas9 systems and other gene editing technologies.
Unanswered Questions
How does this method compare to existing gene editing techniques in terms of efficiency and accuracy?
This article does not provide a direct comparison with other gene editing techniques, leaving the reader to wonder about the relative advantages and disadvantages of this method.
Are there any limitations or challenges associated with using this technology in practical applications?
The article does not address any potential limitations or challenges that may arise when applying this technology in real-world scenarios, leaving room for further exploration and investigation.
Original Abstract Submitted
Described herein are method for generating a vector for editing a cell. The method comprises ligating into a vector that encodes a portion of a gRNA a cassette comprising at least one editing cassette, a promoter, and a gene encoding another portion of the gRNA. Upon ligation, the portion of the gRNA from the editing cassette and the other portion of the gRNA are ligated and form a functional gRNA.